146 related articles for article (PubMed ID: 1590990)
1. Cellular basis of skin allograft rejection: an in vivo model of immune-mediated tissue destruction.
Rosenberg AS; Singer A
Annu Rev Immunol; 1992; 10():333-58. PubMed ID: 1590990
[TBL] [Abstract][Full Text] [Related]
2. Rejection of skin allografts by CD4+ T cells is antigen-specific and requires expression of target alloantigen on Ia- epidermal cells.
Rosenberg AS; Katz SI; Singer A
J Immunol; 1989 Oct; 143(8):2452-6. PubMed ID: 2477443
[TBL] [Abstract][Full Text] [Related]
3. An immunodominant minor histocompatibility alloantigen that initiates corneal allograft rejection.
Haskova Z; Sproule TJ; Roopenian DC; Ksander AB
Transplantation; 2003 Apr; 75(8):1368-74. PubMed ID: 12717232
[TBL] [Abstract][Full Text] [Related]
4. Contributions of direct and indirect T cell alloreactivity during allograft rejection in mice.
Benichou G; Valujskikh A; Heeger PS
J Immunol; 1999 Jan; 162(1):352-8. PubMed ID: 9886406
[TBL] [Abstract][Full Text] [Related]
5. Specific immunosuppression of corneal allograft rejection by combination of anti-VLA-4 and anti-LFA-1 monoclonal antibodies in mice.
Hori J; Isobe M; Yamagami S; Mizuochi T; Tsuru T
Exp Eye Res; 1997 Jul; 65(1):89-98. PubMed ID: 9237869
[TBL] [Abstract][Full Text] [Related]
6. CD4+ T cell-mediated rejection of major histocompatibility complex class I-disparate grafts: a role for alloantibody.
Morton AL; Bell EB; Bolton EM; Marshall HE; Roadknight C; McDonagh M; Bradley JA
Eur J Immunol; 1993 Sep; 23(9):2078-84. PubMed ID: 8103742
[TBL] [Abstract][Full Text] [Related]
7. Rejection of skin allografts by indirect allorecognition of donor class I major histocompatibility complex peptides.
Fangmann J; Dalchau R; Fabre JW
Transplant Proc; 1993 Feb; 25(1 Pt 1):183-4. PubMed ID: 8438266
[No Abstract] [Full Text] [Related]
8. Carcinogen-treated skin allografts rejected by T lymphocytes specific for class I but not class II MHC antigens.
Halliday GM; Odling KA; Muller HK
Cell Immunol; 1993 Oct; 151(2):291-9. PubMed ID: 8402936
[TBL] [Abstract][Full Text] [Related]
9. Sphingosine 1-phosphate receptor agonism impairs skin dendritic cell migration and homing to secondary lymphoid tissue: association with prolonged allograft survival.
Lan YY; Tokita D; Wang Z; Wang HC; Zhan J; Brinkmann V; Thomson AW
Transpl Immunol; 2008 Nov; 20(1-2):88-94. PubMed ID: 18694829
[TBL] [Abstract][Full Text] [Related]
10. IL-5 mediates eosinophilic rejection of MHC class II-disparate skin allografts in mice.
Le Moine A; Surquin M; Demoor FX; Noël JC; Nahori MA; Pretolani M; Flamand V; Braun MY; Goldman M; Abramowicz D
J Immunol; 1999 Oct; 163(7):3778-84. PubMed ID: 10490975
[TBL] [Abstract][Full Text] [Related]
11. A synthetic CD4-CDR3 peptide analog enhances skin allograft survival across a MHC class II barrier.
Koch U; Choksi S; Marcucci L; Korngold R
J Immunol; 1998 Jul; 161(1):421-9. PubMed ID: 9647252
[TBL] [Abstract][Full Text] [Related]
12. Graft rejection by T cells not restricted by conventional major histocompatibility complex molecules.
Dierich A; Chan SH; Benoist C; Mathis D
Eur J Immunol; 1993 Oct; 23(10):2725-8. PubMed ID: 8104801
[TBL] [Abstract][Full Text] [Related]
13. In vivo study of T-cell responses to skin alloantigens in Xenopus using a novel whole-mount immunohistology method.
Ramanayake T; Simon DA; Frelinger JG; Lord EM; Robert J
Transplantation; 2007 Jan; 83(2):159-66. PubMed ID: 17264812
[TBL] [Abstract][Full Text] [Related]
14. Allograft rejection in athymic nude rats by transferred T cell subsets. II. The response of naive CD4+ and CD8+ thoracic duct lymphocytes to an isolated MHC class I disparity.
Bell EB; Rejali D; Whitby EH; Sparshott SM; Yang CP
Transplantation; 1990 Oct; 50(4):690-6. PubMed ID: 1977220
[TBL] [Abstract][Full Text] [Related]
15. The T cell populations mediating rejection of MHC class I disparate skin grafts in mice.
Rosenberg AS
Transpl Immunol; 1993; 1(2):93-9. PubMed ID: 7915953
[No Abstract] [Full Text] [Related]
16. A CD8 DE loop peptide analog prevents graft-versus-host disease in a multiple minor histocompatibility antigen-mismatched bone marrow transplantation model.
Choksi S; Kim JC; Whitaker-Menezes D; Murphy GF; Friedman TM; Korngold R
Biol Blood Marrow Transplant; 2004 Oct; 10(10):669-80. PubMed ID: 15389433
[TBL] [Abstract][Full Text] [Related]
17. Tumor allograft rejection is mainly mediated by CD8+ cytotoxic T lymphocytes stimulated with class I alloantigens in cooperation with CD4+ helper T cells recognizing class II alloantigens.
Tomita Y; Mayumi H; Eto M; Nomoto K
J Immunol; 1990 Mar; 144(6):2425-35. PubMed ID: 1968930
[TBL] [Abstract][Full Text] [Related]
18. Mechanism of rejection of MHC class II-disparate murine skin grafts. I. Immunohistochemical analysis of T-cell subsets infiltrating the site of the graft.
Kobayashi E; Fujiwara M
Transplant Proc; 1992 Feb; 24(1):419-22. PubMed ID: 1531715
[No Abstract] [Full Text] [Related]
19. Specific prolongation of MHC class II disparate skin allografts by in vivo administration of anti-IFN-gamma monoclonal antibody.
Rosenberg AS; Finbloom DS; Maniero TG; Van der Meide PH; Singer A
J Immunol; 1990 Jun; 144(12):4648-50. PubMed ID: 2112572
[TBL] [Abstract][Full Text] [Related]
20. Effector cells must recognize antigens expressed in the graft to cause efficient skin graft rejection in SCID mice.
Wecker H; Grusby MJ; Auchincloss H
Transplantation; 1995 Apr; 59(8):1223-7. PubMed ID: 7732570
[No Abstract] [Full Text] [Related]
[Next] [New Search]
